We are live on ! Find out more
CRVS icon

Corvus Pharmaceuticals
CRVS

164 hedge funds and large institutions have $1.02B invested in Corvus Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 68 funds opening new positions, 55 increasing their positions, 30 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more funds holding in top 10

Funds holding in top 10: 1 → 5 (+4)

185% more capital invested

Capital invested by funds: $359M → $1.02B (+$665M)

172% more first-time investments, than exits

New positions opened: 68 | Existing positions closed: 25

158% more call options, than puts

Call options by funds: $21M | Put options by funds: $8.14M

83% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 30

32% more funds holding

Funds holding: 124 → 164 (+40)

20.94% more ownership

Funds ownership: 62.51% → 83.45% (+21%)

Holders
164
Holders Change
+40
Holders Change %
+32.26%
% of All Funds
2.02%
Holding in Top 10
5
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+400%
% of All Funds
0.06%
New
68
Increased
55
Reduced
30
Closed
25
Calls
$21M
Puts
$8.14M
Net Calls
+$12.9M
Net Calls Change
+$13.2M

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$46M
2
DTC
Deep Track Capital
Connecticut
+$39.8M
3
CC
Commodore Capital
New York
+$36M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$32M
5
B
Braidwell
Connecticut
+$28M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$22.1M
2
Morgan Stanley
Morgan Stanley
New York
-$17.1M
3
MB
MPM BioImpact
Massachusetts
-$17.1M
4
ACM
ADAR1 Capital Management
Texas
-$6.03M
5
Jane Street
Jane Street
New York
-$5.33M
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$105M – – –
BlackRock
2
BlackRock
New York
$90.1M +$17.6M +1,104,061 +22%
State Street
3
State Street
Massachusetts
$52.2M +$12.4M +777,769 +28%
ASP
4
Adams Street Partners
Illinois
$47.9M – – –
VCM
5
Vanguard Capital Management
Pennsylvania
$47.3M +$51.6M +3,234,538 New
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$42.7M +$46M +2,883,195 +8,454%
VC
7
Vivo Capital
California
$41M +$9.12M +571,250 +26%
Morgan Stanley
8
Morgan Stanley
New York
$36.6M -$17.1M -1,069,083 -30%
DTC
9
Deep Track Capital
Connecticut
$36.5M +$39.8M +2,491,539 New
Wellington Management Group
10
Wellington Management Group
Massachusetts
$33.9M +$32M +2,003,834 +637%
PA
11
Perceptive Advisors
New York
$33.5M +$25.5M +1,600,000 +231%
CC
12
Commodore Capital
New York
$33M +$36M +2,258,735 New
FCMV
13
Foresite Capital Management VI
California
$26.8M +$7.18M +450,000 +33%
B
14
Braidwell
Connecticut
$25.6M +$28M +1,752,798 New
Geode Capital Management
15
Geode Capital Management
Massachusetts
$25.1M +$3.83M +239,715 +16%
MB
16
MPM BioImpact
Massachusetts
$24.5M -$17.1M -1,068,796 -39%
Goldman Sachs
17
Goldman Sachs
New York
$22.5M +$15.8M +987,482 +178%
HRCM
18
Hood River Capital Management
Florida
$19.5M +$21.3M +1,335,109 New
BCM
19
Boxer Capital Management
California
$16.1M +$17.6M +1,100,000 New
PCH
20
Polar Capital Holdings
United Kingdom
$15.7M +$17.1M +1,070,174 New
CCM
21
Catalio Capital Management
New York
$13M +$14.2M +891,933 New
Millennium Management
22
Millennium Management
New York
$12.7M +$2.83M +177,592 +26%
Adage Capital Partners
23
Adage Capital Partners
Massachusetts
$11M +$12M +750,000 New
EA
24
Emerald Advisers
Pennsylvania
$10M +$11M +686,216 New
VPM
25
Vanguard Portfolio Management
Pennsylvania
$9.8M +$10.7M +669,895 New
1
2 3 4 5

CRVS Hedge Fund Activity: Q1 2026 in Review

164 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q1 2026, worth a combined $1.02B — up 185% from $359M a quarter earlier.

Buyers outnumbered sellers: 68 funds opened new CRVS positions and 25 closed out — a net gain of 43 holders — while 55 added to existing stakes and 30 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $46M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $22.1M sold.

  • 164 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q1 2026, up from 124 in Q4 2025.
  • Funds reported $1.02B of Corvus Pharmaceuticals stock for Q1 2026, up 185% quarter-over-quarter.
  • 68 funds opened new Corvus Pharmaceuticals positions in Q1 2026 and 25 closed out, a net change of +43 holders.
  • The largest Corvus Pharmaceuticals buyer in Q1 2026 was T. Rowe Price Associates, an estimated $46M added.
  • The largest Corvus Pharmaceuticals seller in Q1 2026 was Point72 Asset Management, an estimated $22.1M sold.

Based on aggregated 13F filings for Q1 2026.